How Sirtuin Levels Change During Behçet Disease

NCT06266247 | Active Not Recruiting

• 2 other identifiers: 06-2023/16KMU-BAP
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Our primary aim in our study is to evaluate the relationship between the activity, which will be evaluated by clinical and standard phase reactants, and the IL-6 and TNF-α levels, which will be measured in serum, in Behçet\'s patients. Our secondary aim was to evaluate Sirtuin-1 in Behcet\'s patients and compare it with the normal population. Our third aim is to find out whether there is a relationship between these values and organ involvement.

Conditions

Behçet Disease; Inflammation; Vasculitis

Keywords

Behçet; inflammation

Outcome Measures

Primary Outcomes (1)

• Our primary aim is to evaluate the relationship between the activity to be evaluated with clinical and standard acute phase reactants and the IL-6 and TNF-α levels to be measured in serum in Behçet's patients.

  Since Behçet's disease is an inflammatory disease, immediate blood samples will be taken from patients presenting to the outpatient clinic. Acute phase reactants, tnf-alpha levels and interleukin-6 levels will be measured. Behçet's disease current activity form 2006 (BDCAF-2006) will be filled and disease activity levels will be evaluated. BDCAF-2006 and acute phase reactants, tnf-alpha levels and interleukin-6 levels will be compared. The same comparison will be made with acute phase reactants, tnf-alpha levels and interleukin-6 levels in the blood obtained from the control group. The difference between both groups will be evaluated

  From enrollment to the end of treatment at 6 months"

Study Arms (1)

patients

OTHER

1. Group: Behcet patients 2. Group: Healty people

Diagnostic Test: Take blood samples

Interventions

Take blood samples DIAGNOSTIC_TEST

Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet\'s disease using biological drugs and not using biological drugs

patients

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients diagnosed with Behçet's disease between the ages of 18-65 who come to the Rheumatology Polyclinic for their normal routine check-up.

You may not qualify if:

• Suffer from other arthritis or joint diseases;
• Combined with severe liver and kidney function damage or metabolic diseases (such as thyroid and parathyroid diseases), affecting bone metabolism;
• Combined with serious cardiovascular and cerebrovascular diseases or chronic kidney diseases;
• Combined with tumour and bone metastasis;
• Taking anticancer drugs or other drugs that affect bone metabolism;
• Pregnant or lactating women;
• Exclude other autoimmune disease

Sponsors & Collaborators

• Karamanoğlu Mehmetbey University: lead

Study Sites (1)

Karamanoğlu Mehmetbey University

Karaman, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Behcet Syndrome; Inflammation; Vasculitis

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases; Uveitis, Anterior; Panuveitis; Uveitis; Uveal Diseases; Eye Diseases; Vascular Diseases; Cardiovascular Diseases; Hereditary Autoinflammatory Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Genetic; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Vascular; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical profesor

Study Record Dates

• First Submitted: January 25, 2024
• First Posted: February 20, 2024
• Study Start: January 15, 2024
• Primary Completion: June 30, 2024
• Study Completion: October 30, 2024
• Last Updated: February 20, 2024

Record last verified: 2024-02

Locations

TU (1)